Autologous Orthogonal IL-2Rbeta-expressing Anti-CD19 CAR T-cells SYNCAR-001 - CISMeF
Autologous Orthogonal IL-2Rbeta-expressing Anti-CD19 CAR T-cells SYNCAR-001NCIt concept
Preferred Label : Autologous Orthogonal IL-2Rbeta-expressing Anti-CD19 CAR T-cells SYNCAR-001;
NCIt synonyms : Autologous OrthoCAR SYNCAR-001; Autologous hoRb-expressing Anti-CD19 CAR T-cells SYNCAR-001; Autologous orthoIL-2Rb-expressing Anti-CD19 CAR T-cells SYNCAR-001; Autologous OrthoIL-2Rbeta-expressing Anti-CD19 CAR T-cells SYNCAR-001; Autologous hoRb-expressing CD19-CAR-T Cells SYNCAR-001;
NCIt definition : A preparation of autologous T-lymphocytes that have been genetically modified and
transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting
the tumor-associated antigen (TAA) CD19 fused to the extracellular, transmembrane
and intracellular signaling domains of the T-cell co-stimulatory receptor CD28 and
the cytoplasmic signaling domain of the zeta chain of the TCR/CD3 complex (CD3-zeta)
and expressing a mutated orthogonal (ortho) interleukin (IL)-2beta receptor (hoRbeta;
hoRb), with potential immunostimulating and antineoplastic activities. Upon administration,
autologous hoRb-expressing anti-CD19 CAR T-cells SYNCAR-001 target and bind to CD19-expressing
tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19
antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage
malignancies. Stimulation of hoRb specifically by orthogonal (ortho) IL-2 STK-009
allows for IL-2 signaling specifically in SYNCAR-001 and leads to increased proliferation,
persistence and anti-tumor activity of SYNCAR-001. This may lead to dose reduction
of SYNCAR-001. hoRb does not respond to the native IL-2 ligand. As STK-009 does not
cause IL-2-mediated signaling in other immune cells, systemic toxicity is limited.;